Cross-sectional study of 421 phase 3 lung and breast cancer trials (2000–2020): adaptive designs were associated with higher odds of primary endpoint success (OR 2.363) but not with significantly shorter primary completion time after adjustment.
RCTn = 421 trials
Purja et al. Adaptive design increased success but does not significantly accelerate confirmatory oncology trials